title: [Post-menopausal osteoporosis: Up-to-date].
abstract: Patients with a high risk of fragility fractures, and those with recent fractures, must receive the highest priority for anti-osteoporotic treatment, because of the consequences of some of these fractures (hip, vertebrae, pelvis, humerus). Both non pharmacological and pharmacological treatments must be used. The duration of the treatment is based on the assessment of fracture risk.
authors.affiliation: Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Inserm U 1153, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
authors.forename: K
authors.initials: K
authors.lastname: Briot
authors.affiliation: Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Inserm U 1153, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. Electronic address: christian.roux@aphp.fr.
authors.forename: C
authors.initials: C
authors.lastname: Roux
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004704:Endocrinology / Q000639:trends; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000628:therapy*; D058866:Osteoporotic Fractures / Q000517:prevention & control; D018579:Patient Selection; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents
keywords: Anti-osteoporotic treatment; Fracture; Ostéoporose post-ménopausique; Post-menopausal osteoporosis; Traitement anti-ostéoporotique